financetom
Business
financetom
/
Business
/
Masimo smartwatches infringe Apple design patents, US jury says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Masimo smartwatches infringe Apple design patents, US jury says
Nov 3, 2024 12:04 PM

Oct 25 (Reuters) - Apple ( AAPL ) convinced a federal

jury on Friday that health monitoring tech company Masimo's ( MASI )

smartwatches infringe two of its design patents.

The jury, in Delaware, agreed with Apple ( AAPL ) that Masimo's ( MASI ) W1

and Freedom watches and chargers willfully violated Apple's ( AAPL )

patent rights in smartwatch designs, awarding the tech giant

$250 in damages. Apple's ( AAPL ) attorneys told the court the "ultimate

purpose" of its lawsuit was to win an injunction against sales

of Masimo's ( MASI ) smartwatches after an infringement ruling.

The jury also determined that Masimo's ( MASI ) watches did not

infringe Apple ( AAPL ) patents covering smartwatch inventions that the

tech giant had accused Masimo ( MASI ) of copying.

Masimo ( MASI ) said in a statement that the company appreciated the

jury's verdict "in favor of Masimo ( MASI ) and against Apple ( AAPL ) on nearly

all issues," and that the decision only applied to a

"discontinued module and charger."

"Apple ( AAPL ) primarily sought an injunction against Masimo's ( MASI )

current products, and the jury's verdict is a victory for Masimo ( MASI )

on that issue," Masimo ( MASI ) said.

Apple ( AAPL ) said in a statement that it was "glad the jury's

decision today will protect the innovations we advance on behalf

of our customers."

Irvine, California-based Masimo ( MASI ) accused Apple ( AAPL ) of hiring

away its employees and stealing its pulse oximetry technology

after discussing a potential collaboration. Masimo ( MASI ) convinced the

U.S. International Trade Commission last year to block imports

of Apple's ( AAPL ) Series 9 and Ultra 2 smartwatches after the

commission found that their technology for reading blood oxygen

levels infringed Masimo's ( MASI ) patents.

Apple ( AAPL ) has appealed the decision and resumed selling the

watches after removing the technology. The tech giant

countersued Masimo ( MASI ) for patent infringement in 2022, alleging

that Masimo ( MASI ) copied Apple Watch features to use in its

smartwatches.

Apple ( AAPL ) also accused Masimo ( MASI ) of using lawsuits at the ITC

and in California to "make way for Masimo's ( MASI ) own watch." Masimo ( MASI )

said Apple's ( AAPL ) patent lawsuit was "retaliatory" and "an attempt to

avoid the court in which the parties have been litigating their

dispute."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dover Delivers Strong Q4 Margins & EPS Beat, Stock Climbs On 2025 Optimism
Dover Delivers Strong Q4 Margins & EPS Beat, Stock Climbs On 2025 Optimism
Jan 30, 2025
Dover Corporation ( DOV ) shares are trading higher on Thursday after the company reported fourth-quarter results. Revenue stood at $1.93 billion, an increase of 1% year-over-year, missing the consensus of $1.95 billion.  Segment earnings margin expanded 50 bps Y/Y to 22.2%. Total adjusted segment EBITDA margin expanded to 24.2% from 23.5% a year ago. Margin improved aided by favourable mix from the high margin, high growth platforms, and strict...
Alterity Therapeutics Says ATH434 Showed Slowing of Clinical Progression in Phase 2 Multiple System Atrophy Study; Shares Up
Alterity Therapeutics Says ATH434 Showed Slowing of Clinical Progression in Phase 2 Multiple System Atrophy Study; Shares Up
Jan 30, 2025
09:39 AM EST, 01/30/2025 (MT Newswires) -- Alterity Therapeutics ( ATHE ) shares were sharply higher Thursday morning after the company said that its ATH434 lead candidate demonstrated 48% slowing of clinical progression in a phase 2 clinical trial in patients with early-stage multiple system atrophy. The result was achieved at the 50 mg dose at week 52 when compared...
US SEC case over massive Allen Stanford fraud ends, judge orders fines
US SEC case over massive Allen Stanford fraud ends, judge orders fines
Jan 30, 2025
* Convicted financier ordered to pay $5.9 billion fine * Fake CDs used in Ponzi scheme * Stanford serving 110-year prison term By Jonathan Stempel Jan 30 (Reuters) - A federal judge ordered an end to the U.S. Securities and Exchange Commission's 16-year-old lawsuit over Allen Stanford's $7.2 billion Ponzi scheme, directing the financier and two former colleagues to pay...
UniQure Gets Favorable Recommendation From Data Monitoring Committee AMT-162 Trial to Treat Amyotrophic Lateral Sclerosis
UniQure Gets Favorable Recommendation From Data Monitoring Committee AMT-162 Trial to Treat Amyotrophic Lateral Sclerosis
Jan 30, 2025
09:47 AM EST, 01/30/2025 (MT Newswires) -- UniQure ( QURE ) said Thursday the Independent Data Monitoring Committee for a phase 1/2 trial of AMT-162 to treat amyotrophic lateral sclerosis caused by mutations in the superoxide dismutase 1 gene recommended going ahead with enrollment in the second group after reviewing safety data from the first group in the study. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved